13F Pro Quality Score

17.8/100

Rank #2,822 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

2.5/100

Profitability

9.1/100

Balance Sheet

3.6/100

Earnings Quality

35.4/100

Free Cash Flow

11.4/100

Institutional Flow

52.5/100

Revenue Scale

9.7/100

Dilution Risk

94.7/100
Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Unusual Activity in FOCL

Events flagged as statistical outliers against FOCL's own multi-year baseline — not fixed dollar thresholds.

  • Score shock2026-08-16

    FOCL quality score dropped 31 points (48→16) on a new filing

    View source filing →
  • Insider cluster2026-08-14

    8 insiders bought $551,000 of FOCL in 30 days — 16.0σ above this company's 2-year norm

    View source filing →

FOCL Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for EDAP TMS SA (FOCL), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores FOCL at 17.8/100 on a 32-signal composite quality model, placing it at rank #2,822 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (2.5) and balance sheet strength (3.6), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), EDAP TMS SA reports quarterly revenue of $13.2M, net income of $-14.5M. Top institutional holders of FOCL by reported 13-F value include Soleus Capital Management, L.P., MORGAN STANLEY, Rock Springs Capital Management, based on the most recent SEC filings. FOCL trades on the Nasdaq exchange and files with the SEC under CIK 1041934. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate FOCL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for EDAP TMS SA directly from SEC EDGAR. EDAP TMS SA's 13F Pro composite quality score has ranged between 16 and 47 since 2026, currently 17.8 — a stable long-term trajectory across 19 quarterly and live scoring snapshots.

Fun facts about EDAP TMS SA

Quirks, history, and lore behind FOCL — the kind of stuff that makes a stock memorable.

  • 1
    The Basics
    A French medical device company · listed on Nasdaq · operating in the urology space · with a global commercial footprint.
  • 2
    The Numbers
    A small-cap company with annual revenue in the range of tens of millions of dollars — the kind of niche medtech that Wall Street only notices when the FDA does.
  • 3
    The History
    Founded in the 1990s in France, it pioneered the use of high-intensity focused ultrasound (HIFU) as a non-invasive treatment — long before the technology was widely accepted.
  • 4
    The Secret
    Its core technology uses focused sound waves to destroy tissue without a single incision — essentially cooking tumors from the outside in, no scalpel required.
  • 5
    The Lore
    Its flagship device has been used to treat prostate cancer patients across multiple continents, and the company spent years navigating FDA approval in the U.S. market.
  • 6
    The Giveaway
    French HIFU pioneer, Nasdaq-listed, known for its Focal One prostate treatment robot — a company whose ticker is literally the name of its star product.
▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$13.2M

Net Income

Q2 2026

$-14.5M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+1.6% YoY
$70.5MFY 2025
FY22 $55.1MFY23 $60.4MFY24 $69.4MFY25 $70.5M

Net Income

-42.1% YoY
$-29.2MFY 2025
FY22 $-2.9MFY23 $-21.2MFY24 $-20.6MFY25 $-29.2M

Operating Income

-11.1% YoY
$-24.7MFY 2025
FY22 $-4.3MFY23 $-19.8MFY24 $-22.2MFY25 $-24.7M

EPS (Diluted)

-41.8% YoY
$-0.78FY 2025
FY22 $-0.09FY23 $-0.57FY24 $-0.55FY25 $-0.78

Total Assets

-11.6% YoY
$79.0MFY 2025
FY22 $101.1MFY23 $91.5MFY24 $89.4MFY25 $79.0M

Total Debt

+95.0% YoY
$26.1MFY 2025
FY22 $8.6MFY23 $7.6MFY24 $13.4MFY25 $26.1M

Op. Cash Flow

-11.6% YoY
$-16.4MFY 2025
FY22 $-3.0MFY23 $-14.7MFY24 $-14.7MFY25 $-16.4M

Get alerted when FOCL's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for EDAP TMS SA including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Companies Similar to FOCL

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

ORGO

Organogenesis Holdings Inc.

30
AI score
Shared smart-money ownership · 3 shared holders
DRIO

DarioHealth Corp.

19
AI score
Similar quality profile
NBTX

Nanobiotix S.A.

28
AI score
Similar quality profile
MTEX

MANNATECH INC

25
AI score
Similar quality profile
RVP

RETRACTABLE TECHNOLOGIES INC

27
AI score
Similar quality profile
SVA

SINOVAC BIOTECH LTD

23
AI score
Similar quality profile
INCR

Intercure Ltd.

29
AI score
Similar quality profile
SRTS

Sensus Healthcare, Inc.

16
AI score
Similar quality profile

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

Put FOCL on your watchlist

Track score changes the day EDAP TMS SA files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is FOCL a good stock to buy?

13F Pro's AI-powered analysis of EDAP TMS SA (FOCL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for FOCL are available on the FOCL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. FOCL is classified as a small company.

Which hedge funds own FOCL?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling FOCL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of EDAP TMS SA's investment landscape.